<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03388125</url>
  </required_header>
  <id_info>
    <org_study_id>Active bleeding</org_study_id>
    <nct_id>NCT03388125</nct_id>
  </id_info>
  <brief_title>Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection</brief_title>
  <official_title>Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherief Abd-Elsalam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management
      of Actively Bleeding Esophageal Varices
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Actual">August 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with controlled bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>The Number of patients with controlled bleeding</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Bleeding Esophageal Varices</condition>
  <arm_group>
    <arm_group_label>Injection Sclerotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5% ethano lamine oleate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-butyl-2-cyanoacrylate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-butyl-2-cyanoacrylate injection group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection Sclerotherapy</intervention_name>
    <description>5% ethanolamine oleate group</description>
    <arm_group_label>Injection Sclerotherapy</arm_group_label>
    <other_name>5% ethanolamine oleate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-butyl-2-cyanoacrylate</intervention_name>
    <description>N-butyl-2-cyanoacrylate injection group</description>
    <arm_group_label>N-butyl-2-cyanoacrylate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cirrhotic patients presented with actively bleeding

        Exclusion Criteria:

          -  other sources of UGIB than esophageal varices, hepatic encephalopathy or
             hepatocellular carcinoma (HCC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Alsebaey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Abdelraouf, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gastroenterology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherief Abd-Elsalam, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hepatology and Gastroenterology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sherief Abd-Elsalam</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2017</study_first_submitted>
  <study_first_submitted_qc>December 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanolamine oleate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

